Navigation Links
LSUHSC research identifies key contributor to Alzheimer's disease process
Date:11/13/2008
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Myriant Technologies LLC Selected for $50 Million Award for Succinic Acid Biorefinery Project 2Enerkem Awarded $50 Million Funding by U.S. Department of Energy for its Mississippi Biorefinery Project 2Enerkem Awarded $50 Million Funding by U.S. Department of Energy for its Mississippi Biorefinery Project 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer 2
Other Biology Technology:The Bill & Melinda Gates Foundation, BIO, and Bio Ventures for Global Health Invite Proteome Systems' CEO to Speak on TB Diagnostics Solutions At Partnering for Global Health Forum, Washington D.C. 2The Bill & Melinda Gates Foundation, BIO, and Bio Ventures for Global Health Invite Proteome Systems' CEO to Speak on TB Diagnostics Solutions At Partnering for Global Health Forum, Washington D.C. 3Helix BioPharma reports Q2 2008 highlights, financial results 2Helix BioPharma reports Q2 2008 highlights, financial results 3Helix BioPharma reports Q2 2008 highlights, financial results 4Helix BioPharma reports Q2 2008 highlights, financial results 5Helix BioPharma reports Q2 2008 highlights, financial results 6Helix BioPharma reports Q2 2008 highlights, financial results 7Helix BioPharma reports Q2 2008 highlights, financial results 8Helix BioPharma reports Q2 2008 highlights, financial results 9Helix BioPharma reports Q2 2008 highlights, financial results 10Helix BioPharma reports Q2 2008 highlights, financial results 11Helix BioPharma reports Q2 2008 highlights, financial results 12Helix BioPharma reports Q2 2008 highlights, financial results 13Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences 2Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences 3Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences 4